Inflammation of Actinic Keratoses Induced by Combination of Carboplatin and Paclitaxel: Two Case Reports

Špela Šuler Baglama; Anja Trajber Horvat; Irena Peteln; Gregor Borut Ernst Jemec

doi:10.1159/000528128

Inflammation of Actinic Keratoses Induced by Combination of Carboplatin and Paclitaxel: Two Case Reports

Case Rep Dermatol. 2022 Dec 7;14(3):362-367. doi: 10.1159/000528128. eCollection 2022 Sep-Dec.

Authors

Špela Šuler Baglama¹, Anja Trajber Horvat¹, Irena Peteln¹, Gregor Borut Ernst Jemec^{2

3}

Affiliations

¹ Department of Dermatology and Venereal Diseases, University Medical Centre Maribor, Maribor, Slovenia.
² Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
³ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Abstract

The observations of a beneficial effect of 5-fluorouracil-induced actinic keratoses (AK) inflammation led to the development of topical fluorouracil, a product registered for the management of AK. A conscientious surveillance of AK inflammation during chemotherapy may conceivably lead to the development of further drugs for treatment of AK. A number of other chemotherapeutics have thus been linked to similar reactions without ensuing development. Here, we describe two further cases linking chemotherapy with carboplatin and paclitaxel to possible anti-AK effects, identifying them as potential treatments. Whether multidrug chemotherapy leads to stronger AK inflammation or cure AK more successfully is currently unknown.

Keywords: Actinic keratoses; Carboplatin; Chemotherapy; Inflammation; Paclitaxel.

Publication types

Case Reports

Grants and funding

This work was not supported by any funding.